Belgian nuclear research centre SCK CEN and Dutch company TerThera have signed an agreement to cooperate on the production of terbium-161, a therapeutic radioisotope promising cancer treatment to patients.
Philippe van Overeem, CEO of TerThera said more clinical research is needed to prove the effects of Terbium-161, which in turn means an increased demand for the radioisotope. Under the agreement, SCK CEN and TerThera will be looking to “accelerate” the development of the treatment.
Want to keep reading?
Register free and get full access to NucNet for 14 days. No card required.
- Daily news briefing on the global nuclear industry
- Weekly, monthly and topical newsletters
- 24/7 coverage during nuclear incidents and safety events
- Full searchable archive, 30,000+ articles since 1991
- SMR and AMR project database
- Analysis, Focus pieces and infographics
- NucNet Style Guide for nuclear reporters and communicators
After the trial, keep a free account for a newsletter and a complimentary Plus article every two weeks. Or see our subscription plans for individuals and organisations.
See subscription options
